Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Next Previous
X
Search
Trial Profile

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
  • Indications Brain metastases; Breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Male breast cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Apr 2024 According to Trial design presented at the 115th Annual Meeting of the American Association for Cancer Research, the first patient was enrolled in January 2022 and accrual of patients is ongoing
    • 10 Apr 2024 Trial design presented at the 115th Annual Meeting of the American Association for Cancer Research
    • 14 Apr 2023 Planned End Date changed from 30 Apr 2023 to 30 Apr 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top